论文部分内容阅读
目的探讨氟伐他汀联合非诺贝特治疗糖尿病合并高血脂的临床疗效。方法选取2014年11月—2015年11月在我院采用氟伐他汀联合非诺贝特治疗的56例糖尿病并发高血脂患者作为联合组,同时选取单用氟伐他汀治疗的45例糖尿病并发高血脂患者作为单用组,比较2组患者的临床治疗效果。结果联合组患者临床治疗总有效明显高于单用组(P<0.05)。治疗前,2组患者TC、TG、LDL-C、HDL-C等血脂指标以及FPG和2 hPG等血糖指标比较差异无统计学意义(P>0.05),治疗后联合组患者上述指标明显优于单用组(P<0.05)。2组患者不良反应均较短暂且轻微,未见肝肾功能障碍。结论氟伐他汀联合非诺贝特在治疗糖尿病并发高血脂方面不仅可提高临床效果,还能明显改善患者血糖和血脂水平,安全可靠。
Objective To investigate the clinical efficacy of fluvastatin combined with fenofibrate in the treatment of diabetic patients with hyperlipidemia. Methods Fifty-six patients with diabetes mellitus and hyperlipidemia treated with fluvastatin combined with fenofibrate in our hospital from November 2014 to November 2015 were selected as the combined group. Forty-five patients with diabetes treated with fluvastatin alone were enrolled in this study. Lipid patients as a single group, the clinical efficacy of two groups of patients were compared. Results The total effective rate of clinical treatment in combined group was significantly higher than that in single group (P <0.05). Before treatment, TC, TG, LDL-C, HDL-C and other blood lipid indicators, as well as FPG and 2 hPG, had no significant difference between the two groups (P> 0.05). After treatment, the above indexes were significantly better Group alone (P <0.05). Adverse reactions in both groups were short and mild, no liver and kidney dysfunction. Conclusion Fluvastatin combined with fenofibrate can not only improve the clinical efficacy in the treatment of diabetes complicated with hyperlipidemia, but also improve the level of blood glucose and blood lipid obviously and be safe and reliable.